Investors & Media


Altamira Therapeutics is dedicated to developing therapeutics that address important unmet medical needs. The Company is currently active in RNA therapeutics, allergy and viral infections, and inner ear disorders. The Company was founded in 2003 and is headquartered in Hamilton, Bermuda with its main operations in Basel, Switzerland. The shares of Altamira Therapeutics Ltd. trade on the NASDAQ Capital Market under the symbol “CYTO.”

Latest Events

Meet Altamira: Fly exclusive interview with CEO Thomas Meyer

Read Article

Altamira Therapeutics Issues Spring 2022 Shareholder Letter

View PDF

Stock Quote


CYTO Business Update

Recent Press Releases

Investor Contact

Primary IR Contacts
U.S Tel: 800-460-0183